Could This Company Challenge Eli Lilly and Novo Nordisk in the Weight Loss Market?

Novo Nordisk (NYSE:NVO) has been a pioneer in the market for weight loss drugs, but Eli Lilly (NYSE:LLY) has since emerged as the leader. Both drugmakers have deep pipelines that could allow them to remain ahead of their competitors in the coming years as the anti-obesity area continues to expand rapidly. But could another pharmaceutical giant eventually take the lead?

One of the more likely candidates to do so might be Roche (OTC:RHHBY), and recent developments have shown just how promising its leading candidate is. Let's find out what this could mean for investors looking to capitalize on the weight loss market.

Image source: The Motley Fool.

Excellent mid-stage results

In January, Roche posted strong Phase 2 weight loss results for enicepatide (also known as CT-388). The drug led to a mean, placebo-adjusted weight loss of 22.5% over 48 weeks. Comparing across clinical trials is never ideal, but it can be useful. And, in this case, doing so can help us appreciate just how promising enicepatide looks. In a head-to-head study, Zepbound achieved a mean weight loss of 20.2% over 72 weeks, compared with 13.7% for Novo's semaglutide. So, in just 48 weeks, enicepatide produced weight-loss results that seem to compare favorably with Zepbound's efficacy over 72 weeks, although, again, these results come from separate trials and they aren't directly comparable.

There are other caveats to keep in mind. There is no guarantee that Roche's enicepatide will post similarly strong data in larger, longer Phase 3 studies. However, recently, it did it again in another Phase 2 trial, this time in patients with diabetes who were either overweight or obese. Roche noted that patients on enicepatide recorded HbA1c reductions of up to 2.65 percentage points after 48 weeks. By contrast, patients on tirzepatide had HbA1c reductions of up to 2.37 percentage points after 52 weeks in a Phase 3 clinical study. The same caveats as above apply. The point, though, is that the data on enicepatide so far are very encouraging.

Could Roche take the lead?

Clinical trial data so far suggest that Roche's enicepatide could be somewhat competitive in both diabetes and weight loss, which, together, form an enormous market. Consider that tirzepatide and semaglutide posted combined sales of over $50 billion last year, mostly generated from these two markets. And as this space grows, there will be room for multiple winners over the medium term. Note that enicepatide is a dual GLP-1 and GIP agonist, like tirzepatide.

But even though enicepatide works on the same two hormone receptors as tirzepatide, it is designed in such a way that, in theory, it could have a more sustained, uninterrupted effect rather than wearing off quickly, potentially leading to greater efficacy. Or at least, that's Roche's hypothesis, and so far, there is some evidence for its validity. But is it enough to overtake Eli Lilly and Novo Nordisk? Probably not, and here is why.

Both pharmaceutical leaders still have deep pipelines in this area. For instance, Novo Nordisk is close to earning approval for CagriSema, a medicine that produced greater weight loss than semaglutide in a head-to-head Phase 3 study. The company also boasts other exciting candidates, such as zenagamtide, which is in Phase 3 trials. Eli Lilly arguably has an even stronger pipeline. The company's retatrutide posted outstanding Phase 3 results that look even better than Zepbound. And that's just the tip of the iceberg.

Is Roche stock a Buy?

Then again, Roche does not need to become the leader in the diabetes or weight loss market to deliver excellent returns over the medium term. The company is already performing pretty well. In the first six months of the year, Roche's revenue grew by 6% year over year (in constant currency) to 30.4 billion Swiss francs ($36.6 billion), while its core earnings per share were 10.85 Swiss francs ($13.04), 9% higher than the year-ago period. Roche boasts several products that are performing well, including Vabysmo, which treats several eye-related conditions, Xolair, a medicine for allergic asthma, and Ocrevus, a multiple sclerosis treatment.

Roche also has a diversified healthcare business spanning the diagnostics industry. Finally, the company boasts a deep pharmaceutical pipeline that includes several exciting products beyond enicepatide. The company should expand its product lineup over the medium term and continue to post consistent revenue and earnings growth, while potentially delivering competitive returns.

Prosper Junior Bakiny has positions in Eli Lilly and Novo Nordisk. The Motley Fool has positions in and recommends Eli Lilly and Novo Nordisk. The Motley Fool recommends Roche Holding AG. The Motley Fool has a disclosure policy.